Adjust Font Sizing:

Positive Results from IH Phase 3 Study of Xywav

October 26th, 2020

Jazz Pharmaceuticals plc announced positive top-line results from their Phase 3 double-blind, multicenter, placebo-controlled, randomized withdrawal study evaluating the efficacy and safety of an investigational use of Xywav™ in adult patients with idiopathic hypersomnia.

Patients in the study had excessive daytime sleepiness typical of idiopathic hypersomnia. All patients were treated with Xywav™  and reported clinically meaningful improvements in the Epworth Sleepiness Scale (ESS).

Xywav™ was approved in July 2020 by the FDA for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.

To learn more about Xywav™ or this IH study, read the Jazz press release.

# # #
Date Created: October 26th, 2020
Last Updated: October 26th, 2020